Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 95

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 95
---
                4,800          
  Option pricing models used                     Black-Scholes                Black-Scholes      Black-Scholes  
  Share price                                    5,040.00                     $263.50            $63.25         
  Exercise price of warrants issued in year      $ 5,800.00 /$ 10,000.00      $375.00            $62.50         
  Contractual life                               3 years                      3 years            3 years        
  Expected life                                  3 years                      3 years            3 years        
  Volatility                                     75.00                        80.00              60             
  Expected dividend yield                        0                            0                  0              
  Risk free rate                                 4.35                         4.04               4.06           

  The share price used in the determination of the fair value of            

  Volatility was calculated with reference to the historic share               
  price volatility of comparable companies measured over a three-year period.  
 ───────────────────────────────────────────────────────────────────────────────

Number and original
price of warrants have been adjusted to reflect the ratio change of ADS’s to ordinary shares that occurred on 5 July 2023 and 4
October 2024.

26 Capital
commitments

The Group had no capital commitments
at 31 December 2024, 31 December 2023 and 31 December 2022.

27 Related
party transactions

There were no related party transactions
in the current or prior periods other than Directors’ remuneration.

28 Contingent
liabilities

The
Company entered into an Arrangement Agreement with Bioasis on 13 December 2022 as amended on 18 December 2022. Under the agreement the
Company agreed to acquire the entire issued share capital of Bioasis for consideration of, in aggregate, approximately C$ 7.4 225,000

As
at 31 December 2023 and 31 December 2022 the Company had a contingent liability of $ 225,000

29 Ultimate
controlling party

The Directors do not consider that there
is an ultimate controlling party.

30 Post
Balance Sheet Events

On 17 January,
2025, we entered into an ELOC with C/M Capital Master Fund LP (“ C/M”) pursuant to which we have the right, but not the
obligation, to sell to C/M, and C/M is obligated to purchase, up to $35